Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
Ixabepilone and Pemetrexed/Solid Tumors
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT01170871
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Los Angeles County+University of Southern California Medical Center, Los Angeles, California, United States
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT01168232
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
- First Posted Date
- 2010-04-01
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT01097642
- Locations
- 🇺🇸
The Methodist Hospital Cancer Center, Houston, Texas, United States
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT01084057
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸South Pasadena Cancer Center, South Pasadena, California, United States
Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT01079793
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
Ixabepilone + Carboplatin Metastatic Breast Cancer
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 103
- Registration Number
- NCT01075100
- Locations
- 🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸Missouri Cancer Associates, Columbia, Missouri, United States
🇺🇸Southwest Cancer care, Murrieta, California, United States
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 6
- Registration Number
- NCT01057212
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
- First Posted Date
- 2009-12-07
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 20
- Registration Number
- NCT01027208
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 54
- Registration Number
- NCT01019577
Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 25
- Registration Number
- NCT01018966
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.